John K Fallon1, Philip C Smith1, Cindy Q Xia2, Mi-Sook Kim3. 1. Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, USA. 2. Department of Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, Massachusetts, 02139, USA. 3. Department of Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co., 40 Landsdowne Street, Cambridge, Massachusetts, 02139, USA. mi-sook.kim@takeda.com.
Abstract
PURPOSE: The expression levels of several efflux drug transporters in the liver and kidney were evaluated across species to address potential roles of the transporters in species dependent excretion of drugs and their metabolites. METHODS: Four efflux transporters, namely MDR1/P-gp, BCRP/Bcrp, MRP2/Mrp2 and MRP3/Mrp3 in liver and kidney in three preclinical species and humans were quantified using targeted quantitative proteomics by isotope dilution nanoLC-MS/MS. RESULTS: In liver, the level of P-gp was highest in monkey and lowest in rat. The concentration of BCRP/Bcrp was highest in dog followed by monkey. MRP2/Mrp2 level was highest in monkey and rat, whereas MRP3/Mrp3 levels were similar in human, monkey and dog. In the kidney, the concentrations of MDR1/P-gp in human and monkey were roughly 2 to 3-fold higher than in rat and dog. In rat, BCRP/Bcrp concentrations were substantially higher than in any of the other species. MRP2/Mrp2 concentrations were similar across species, whereas expression of MRP3/Mrp3 was highest in rat. CONCLUSION: Overall, the results indicated that the pattern of hepatic and renal expression of the transporters was quite species dependent. This information should be helpful in the estimation of transport mediated drug and metabolites excretion in liver and kidney across species.
PURPOSE: The expression levels of several efflux drug transporters in the liver and kidney were evaluated across species to address potential roles of the transporters in species dependent excretion of drugs and their metabolites. METHODS: Four efflux transporters, namely MDR1/P-gp, BCRP/Bcrp, MRP2/Mrp2 and MRP3/Mrp3 in liver and kidney in three preclinical species and humans were quantified using targeted quantitative proteomics by isotope dilution nanoLC-MS/MS. RESULTS: In liver, the level of P-gp was highest in monkey and lowest in rat. The concentration of BCRP/Bcrp was highest in dog followed by monkey. MRP2/Mrp2 level was highest in monkey and rat, whereas MRP3/Mrp3 levels were similar in human, monkey and dog. In the kidney, the concentrations of MDR1/P-gp in human and monkey were roughly 2 to 3-fold higher than in rat and dog. In rat, BCRP/Bcrp concentrations were substantially higher than in any of the other species. MRP2/Mrp2 concentrations were similar across species, whereas expression of MRP3/Mrp3 was highest in rat. CONCLUSION: Overall, the results indicated that the pattern of hepatic and renal expression of the transporters was quite species dependent. This information should be helpful in the estimation of transport mediated drug and metabolites excretion in liver and kidney across species.
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Christopher J Kochansky; Yuan-Qing Xia; Sui Wang; Brian Cato; Mellissa Creighton; Stella H Vincent; Ronald B Franklin; James R Reed Journal: Drug Metab Dispos Date: 2005-09-23 Impact factor: 3.922
Authors: K Ogawa; H Suzuki; T Hirohashi; T Ishikawa; P J Meier; K Hirose; T Akizawa; M Yoshioka; Y Sugiyama Journal: Am J Physiol Gastrointest Liver Physiol Date: 2000-03 Impact factor: 4.052
Authors: Christian Zimmermann; Koen van de Wetering; Evita van de Steeg; Els Wagenaar; Conchita Vens; Alfred H Schinkel Journal: Drug Metab Dispos Date: 2008-01-07 Impact factor: 3.922
Authors: Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba Journal: J Pharmacol Exp Ther Date: 2019-06-24 Impact factor: 4.030
Authors: Corbin G Thompson; John K Fallon; Michelle Mathews; Paige Charlins; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Nithya Srinivas; Amanda Schauer; Craig Sykes; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Bridget L Morse; John K Fallon; Anil Kolur; Andrew T Hogan; Philip C Smith; Kathleen M Hillgren Journal: AAPS J Date: 2021-04-26 Impact factor: 4.009
Authors: Raju Khatri; John K Fallon; Rebecca J B Rementer; Natasha T Kulick; Craig R Lee; Philip C Smith Journal: J Pharmacol Toxicol Methods Date: 2019-05-31 Impact factor: 1.950
Authors: Bhagwat Prasad; Katherine Johnson; Sarah Billington; Caroline Lee; Git W Chung; Colin D A Brown; Edward J Kelly; Jonathan Himmelfarb; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2016-09-12 Impact factor: 3.922
Authors: Jacqueline Bezençon; Chitra Saran; Janine Hussner; James J Beaudoin; Yueping Zhang; Hong Shen; John K Fallon; Philip C Smith; Henriette E Meyer Zu Schwabedissen; Kim L R Brouwer Journal: J Pharm Sci Date: 2020-10-13 Impact factor: 3.534
Authors: Raju Khatri; Natasha Kulick; Rebecca J B Rementer; John K Fallon; Craig Sykes; Amanda P Schauer; Melina M Malinen; Merrie Mosedale; Paul B Watkins; Angela D M Kashuba; Kim A Boggess; Philip C Smith; Kim L R Brouwer; Craig R Lee Journal: J Pharm Sci Date: 2020-09-12 Impact factor: 3.534
Authors: Manisha Nautiyal; Rani J Qasem; John K Fallon; Kristina K Wolf; Jingli Liu; Darlene Dixon; Philip C Smith; Merrie Mosedale Journal: Toxicol In Vitro Date: 2020-10-03 Impact factor: 3.500